Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease.
Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease.
复制标题
DOI：
10.33393/jcb.2022.2328
复制
发表时间：
2022-01
影响因子：
--
通讯作者：
Vietri MT
中科院分区：
文献类型：
--
作者：
Albanese L;Caliendo G;D'Elia G;Passariello L;Molinari AM;Napoli C;Vietri MT
Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease.
